{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "marketState": "REGULAR", "regularMarketChangePercent": 0.0, "regularMarketPrice": 22.8, "exchange": "FRA", "shortName": "BICYCLE THERAP. SP.ADR/1", "longName": "Bicycle Therapeutics plc", "messageBoardId": "finmb_72510621", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "regularMarketTime": 1683801378, "earningsTimestamp": 1683198000, "earningsTimestampStart": 1690979400, "earningsTimestampEnd": 1691411400, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -3.79, "epsForward": -4.39, "epsCurrentYear": -3.79, "priceEpsCurrentYear": -6.015831, "sharesOutstanding": 30043500, "bookValue": 9.064, "fiftyDayAverage": 21.856, "fiftyDayAverageChange": 0.94399834, "fiftyDayAverageChangePercent": 0.043191724, "twoHundredDayAverage": 23.626, "twoHundredDayAverageChange": -0.8260002, "twoHundredDayAverageChangePercent": -0.03496149, "marketCap": 718651392, "forwardPE": -5.1936216, "priceToBook": 2.5154457, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "1.9 - Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1558936800000, "priceHint": 2, "regularMarketChange": 0.0, "regularMarketDayHigh": 22.8, "regularMarketDayRange": "20.4 - 22.8", "regularMarketDayLow": 20.4, "regularMarketVolume": 500, "regularMarketPreviousClose": 22.8, "bid": 21.4, "ask": 22.6, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 20.4, "averageDailyVolume3Month": 16, "averageDailyVolume10Day": 90, "fiftyTwoWeekLowChange": 7.5999994, "fiftyTwoWeekLowChangePercent": 0.49999997, "fiftyTwoWeekRange": "15.2 - 33.2", "fiftyTwoWeekHighChange": -10.400002, "fiftyTwoWeekHighChangePercent": -0.31325305, "fiftyTwoWeekLow": 15.2, "fiftyTwoWeekHigh": 33.2, "symbol": "50BA.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Portway Building", "address2": "Blocks A & B Granta Park Great Abington", "city": "Cambridge", "zip": "CB21 6GS", "country": "United Kingdom", "phone": "44 1223 261 503", "website": "https://www.bicycletherapeutics.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. It is developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; BT5528, a BTC that is in a Phase I/II clinical trial targeting Ephrin type-A receptor 2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. The company also develops THR-149, a plasma kallikrein inhibitor for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA; and BT7401, a multivalent CD137 agonist. In addition, it collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, dementia, central nervous system, neuromuscular, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca AB, Sanofi, Oxurion NV, and the Dementia Discovery Fund, as well as with Ionis Pharmaceuticals, Inc.; and a discovery collaboration and license agreement with Genentech Inc. for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.", "fullTimeEmployees": 236, "companyOfficers": [{"maxAge": 1, "name": "Dr. Kevin  Lee M.B.A., Ph.D.", "age": 53, "title": "CEO & Exec. Director", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": {"raw": 1314332, "fmt": "1.31M", "longFmt": "1,314,332"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Lee H. Kalowski M.B.A., MBA", "age": 41, "title": "Pres & CFO", "yearBorn": 1981, "fiscalYear": 2022, "totalPay": {"raw": 879993, "fmt": "879.99k", "longFmt": "879,993"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE", "age": 71, "title": "Co-Founder, Non-Exec. Director & Member of Scientific Advisory Board", "yearBorn": 1951, "fiscalYear": 2022, "totalPay": {"raw": 55000, "fmt": "55k", "longFmt": "55,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Alistair  Milnes", "age": 48, "title": "Chief Operating Officer", "yearBorn": 1974, "fiscalYear": 2022, "totalPay": {"raw": 796089, "fmt": "796.09k", "longFmt": "796,089"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Michael  Skynner B.sc. Ph.d., Ph.D.", "age": 52, "title": "Chief Technology Officer", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": {"raw": 881008, "fmt": "881.01k", "longFmt": "881,008"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Christian  Heinis", "title": "Scientific Founder", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Nicholas  Keen Ph.D.", "age": 54, "title": "Chief Scientific Officer", "yearBorn": 1968, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. David E. Borah CFA", "title": "VP of Capital Markets & Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Zafar  Qadir", "title": "Gen. Counsel", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Gillian  Langford", "title": "Head of Clinical and Project Management", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}